Chronic Periodontitis Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

(Albany, US) September 21, 2026- DelveInsight's, "Chronic Periodontitis Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Periodontitis Pipeline Report
• In September 2026 - Emanate Biomedical, Inc. received FDA 510(k) clearance for Perio PODSTM, an at-home periodontal wound dressing designed to protect periodontal tissue following non-surgical periodontal procedures. The patient-matched dental trays contain an engineered hydrogel that creates a temporary physical barrier during healing. In a 45-patient investigational randomized controlled trial, Perio PODS was associated with greater reductions in periodontal pocket depth and markers of gingival inflammation compared with periodontal debridement alone.
• In September 2026 - Colgate-Palmolive initiated a Phase III multicenter randomized clinical trial evaluating a multi-component oral hygiene regimen as an adjunct to non-surgical periodontal treatment in patients with Stage II periodontitis. The study is planned to enroll 100 participants and will assess periodontal outcomes compared with a placebo oral hygiene regimen
• DelveInsight's Chronic Periodontitis Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Periodontitis treatment.
• The leading Chronic Periodontitis Companies such as Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc and others.
• Promising Chronic Periodontitis Therapies such as Minocycline HCl 2.1%, PerioChip ®, Probiotic, Inersan, Doxycycline, Lactobacillus brevis CD2 Lozenges, Flurbiprofen, Chlorhexidine and others.

Learn how leading Chronic Periodontitis Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Periodontitis Overview
Periodontal disease and dental caries are the most common diseases in the oral cavity. Chronic periodontitis is one of the periodontal diseases. It is a long-lasting inflammatory disease affecting the soft and hard tissues around the teeth and it is common worldwide. This disease is related to common and preventable biological risk factors (e.g., high blood pressure, high blood cholesterol, diabetes, genetic factors, and obesity) and behavioral risk factors (e.g., an unhealthy diet, physical inactivity, and tobacco use). Chronic periodontitis is ideally diagnosed at the beginning of the disease.

Chronic Periodontitis Emerging Drugs Profile
• ST 266: Noveome
ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.

The Chronic Periodontitis Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Periodontitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Periodontitis Treatment.
• Chronic Periodontitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Periodontitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Periodontitis market.

From early-stage research to late-phase Chronic Periodontitis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs- Download now! @ https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Periodontitis Companies
Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc and others.

Chronic Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous

Chronic Periodontitis Products have been categorized under various Molecule types such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Stay updated with the latest Chronic Periodontitis Pipeline Insights! @ Chronic Periodontitis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Periodontitis Pipeline Report
• Coverage- Global
• Chronic Periodontitis Companies- Amyndas Pharmaceuticals, Takeda, CSL Behring, Vaxcyte, Noveome, Perioc and others.
• Chronic Periodontitis Therapies- Minocycline HCl 2.1%, PerioChip ®, Probiotic, Inersan, Doxycycline, Lactobacillus brevis CD2 Lozenges, Flurbiprofen, Chlorhexidine and others.
• Chronic Periodontitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Periodontitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Chronic Periodontitis Treatment, visit @ Chronic Periodontitis Drugs- https://www.delveinsight.com/sample-request/chronic-periodontitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Periodontitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Periodontitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II)
8. Ciclosporin topical gel: Perioc
9. Mid Stage Products (Phase I/II)
10. Mid Stage Products (Phase II)
11. Early Stage Products (Phase I)
12. Preclinical Stage Products
13. VAX PG: Vaxcyte
14. Inactive Products
15. Chronic Periodontitis Key Companies
16. Chronic Periodontitis Key Products
17. Chronic Periodontitis- Unmet Needs
18. Chronic Periodontitis- Market Drivers and Barriers
19. Chronic Periodontitis- Future Perspectives and Conclusion
20. Chronic Periodontitis Analyst Views
21. Chronic Periodontitis Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.